374 related articles for article (PubMed ID: 22362824)
21. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
[TBL] [Abstract][Full Text] [Related]
22. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
[TBL] [Abstract][Full Text] [Related]
25. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
26. Experience from the German pegvisomant observational study.
Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.
Buchfelder M; van der Lely AJ; Biller BMK; Webb SM; Brue T; Strasburger CJ; Ghigo E; Camacho-Hubner C; Pan K; Lavenberg J; Jönsson P; Hey-Hadavi JH
Eur J Endocrinol; 2018 Dec; 179(6):419-427. PubMed ID: 30325178
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
31. Pregnancy in acromegaly patients treated with pegvisomant.
van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
[TBL] [Abstract][Full Text] [Related]
32. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
33. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
34. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
35. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
36. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
[TBL] [Abstract][Full Text] [Related]
37. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
[TBL] [Abstract][Full Text] [Related]
38. Experience from the Argentine Pegvisomant Observational Study: preliminary data.
García Basavilbaso N; Guitelman M; Nagelberg A; Stalldecker G; Carabelli A; Bruno O; Danilowitz K; Manavela M; Mallea Gil S; Ballarino C; Guelman R; Katz D; Fidalgo S; Leal R; Fideleff H; Servidio M; Bruera D; Librandi F; Chervin A; Vitale M; Basso A
Front Horm Res; 2010; 38():42-49. PubMed ID: 20616494
[TBL] [Abstract][Full Text] [Related]
39. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
40. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
